CO5550435A2 - Compuestos de tiazol para el tratamiento de transtornos neu- rodegenerativos - Google Patents

Compuestos de tiazol para el tratamiento de transtornos neu- rodegenerativos

Info

Publication number
CO5550435A2
CO5550435A2 CO05031337A CO05031337A CO5550435A2 CO 5550435 A2 CO5550435 A2 CO 5550435A2 CO 05031337 A CO05031337 A CO 05031337A CO 05031337 A CO05031337 A CO 05031337A CO 5550435 A2 CO5550435 A2 CO 5550435A2
Authority
CO
Colombia
Prior art keywords
moiety
alkyl
residue
alkoxy
cycloalkyl
Prior art date
Application number
CO05031337A
Other languages
English (en)
Inventor
Liang Chen Yuhpyng
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of CO5550435A2 publication Critical patent/CO5550435A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/54—Nitrogen and either oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

1.- Un compuesto, o sus sales farmacéuticamente aceptables, de fórmula: en la que:A se selecciona de los restos -C(=O)C(=O)-, -(C=O)NR9-, -C(=O)Z-, -C(=S)Z-, -C(=NR5)Z-, y -S(O)2-;en los que Z es un resto -CH2-, un resto -CH(OH)-, un resto -CH(OC(=O)R11)-, un resto -CH(NR9R10)-, un resto CH(CH2(OH))-, un resto -CH(CH(alquilo de C1-C4) (OH))-, o un resto -CH(C(alquilo de C1-C4) ( alquilo de C1-C4) (OH))-;R1 se selecciona de un resto alquilo de C1-C20 y un resto -alcoxi de C1-C20, un resto cicloalquilo de C3-C8, un resto cicloalquenilo de (C4-C8), un resto bi- o tricicloalquilo de (C5-C11), un resto bi- o tricicloalquenilo de (C7-C11), un resto heterocicloalquilo (de 3-8 miembros) , un resto arilo de (C6-C14) , o un resto heteroarilo (de 5-14 miembros), en el que dichos restos alquilo y alcoxi contienen opcionalmente cada uno de uno a cinco dobles o triples enlaces, y en el que cada átomo de hidrógeno de dichos grupos alquilo y alcoxi está opcionalmente reemplazado con un átomo de flúor;en la que cuando R1 es un grupo alquilo o alcoxi, R1 está opcionalmente sustituido con de uno a tres sustituyentes R1a, y en la que cuando R1 es un grupo cicloalquilo, cicloalquenilo, bi- o tricicloalquilo, bi- o tricicloalquenilo, heterocicloalquilo, arilo, o heteroarilo, entonces R1 está opcionalmente sustituido con de uno a tres sustituyentes R1b;R1a se selecciona independientemente en cada caso de los restos -OH, -alquilo de C1-C6 que independiente y opcionalmente contiene de uno a tres dobles o triples enlaces, -alcoxi de C1-C6 que independiente y opcionalmente contiene de uno a tres dobles o triples enlaces, -Cl, -F, -Br, -I, -CN, -NO2, -NR9R10, -C(=O)NR9R10, -S(O)nNR9R10, C(=O)R11, -S(O)nR11, -C(=O)OR12, -cicloalquilo de C3-C8, cicloalquenilo de C4-C8, -bi- o -tricicloalquilo de (C5-C11), -bi- o -tricicloalquenilo de (C7-C11), heterocicloalquilo (de 3-8 miembros), -arilo de (C6-C14), heteroarilo (de 5-14 miembros), -ariloxi de (C6-C14), y -heteroariloxi (de 5-14 miembros), en el que dichos grupos alquilo, alcoxi, cicloalquilo, cicloalquenilo, bi- o trici-cloalquilo, bi- o tricicloalquenilo, heterocicloalquilo, arilo, ...
CO05031337A 2002-10-09 2005-04-08 Compuestos de tiazol para el tratamiento de transtornos neu- rodegenerativos CO5550435A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41740002P 2002-10-09 2002-10-09
US46320903A 2003-06-17 2003-06-17

Publications (1)

Publication Number Publication Date
CO5550435A2 true CO5550435A2 (es) 2005-08-31

Family

ID=35306299

Family Applications (1)

Application Number Title Priority Date Filing Date
CO05031337A CO5550435A2 (es) 2002-10-09 2005-04-08 Compuestos de tiazol para el tratamiento de transtornos neu- rodegenerativos

Country Status (28)

Country Link
US (1) US20040152747A1 (es)
EP (1) EP1551815A1 (es)
JP (1) JP2006504796A (es)
KR (1) KR20050070046A (es)
CN (1) CN1688557A (es)
AP (1) AP2005003274A0 (es)
AR (1) AR043051A1 (es)
AU (1) AU2003265068A1 (es)
BR (1) BR0314611A (es)
CA (1) CA2501803A1 (es)
CO (1) CO5550435A2 (es)
CR (1) CR7785A (es)
EC (1) ECSP055719A (es)
GT (1) GT200300219A (es)
IS (1) IS7738A (es)
MA (1) MA27451A1 (es)
MX (1) MXPA05002420A (es)
NL (1) NL1024499C2 (es)
NO (1) NO20052223L (es)
OA (1) OA12937A (es)
PA (1) PA8585001A1 (es)
PE (1) PE20040640A1 (es)
PL (1) PL376171A1 (es)
TN (1) TNSN05104A1 (es)
TW (1) TW200420550A (es)
UY (1) UY28011A1 (es)
WO (1) WO2004033439A1 (es)
ZA (1) ZA200502841B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2842523A1 (fr) * 2002-07-17 2004-01-23 Sanofi Synthelabo Derives d'acylaminothiazole, leur preparation et leur application en therapeutique
BRPI0409721A (pt) * 2003-05-12 2006-05-02 Pfizer Prod Inc compostos de isoxazol e isotiazol para o tratamento de distúrbios neurodegenerativos
EP1653952A4 (en) * 2003-08-06 2007-04-04 Pfizer Prod Inc OXAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEEGENERATIVE DISORDER
FR2865206B1 (fr) * 2004-01-16 2009-02-06 Sanofi Synthelabo Derives d'acylaminothiazole, leur preparation et leur application en therapeutique
JP2007517840A (ja) * 2004-01-16 2007-07-05 サノフイ−アベンテイス アシルアミノチアゾール誘導体、それらの調製方法及び治療における該誘導体の使用
FR2873374B1 (fr) * 2004-07-22 2006-10-20 Sanofi Synthelabo Derives d'acylaminothiazole, leur preparation et leur application en therapeutique
FR2873370B1 (fr) * 2004-07-22 2006-10-20 Sanofi Synthelabo Derives d'acylaminothiazole, leur preparation et leur application en therapeutique
JP4813371B2 (ja) 2004-01-16 2011-11-09 サノフイ−アベンテイス アシルアミノチアゾール誘導体及びβ−アミロイド阻害剤としてのこれらの使用
FR2865207B1 (fr) * 2004-01-16 2008-10-17 Sanofi Synthelabo Derives d'acylaminothiazole, leur preparation et leur application en therapeutique
RS50595B (sr) * 2004-03-23 2010-05-07 Pfizer Products Incorporated Jedinjenja imidazola za lečenje neurodegenerativnih poremećaja
US7220865B2 (en) * 2004-04-01 2007-05-22 Pfizer Inc Isoxazole-and isothiazole-amine compounds for the treatment of neurodegenerative disorders
US7384968B2 (en) 2004-04-01 2008-06-10 Pfizer Inc. Thiazole-amine compounds for the treatment of neurodegenerative disorders
AU2005272815A1 (en) 2004-08-13 2006-02-23 Genentech, Inc. Thiazole based inhibitors of ATP-utilizing enzymes
BRPI0611029A2 (pt) * 2005-05-24 2010-08-10 Serono Lab derivados de tiazol e uso dos mesmos
FR2887879B1 (fr) * 2005-07-01 2008-09-26 Trophos Sa Nouveaux composes chimiques et leurs utilisations comme medicament,particulierement dans le traitement des maladies neurodegeneratives
EP1940802A2 (en) * 2005-09-22 2008-07-09 Pfizer Products Inc. Imidazole compounds for the treatment of neurological disorders
EP1968597A4 (en) * 2005-12-01 2012-01-11 Scripps Research Inst COMPOSITIONS AND METHODS FOR INDUCING NEURONAL DIFFERENTIATION
CA2636077C (en) * 2006-01-18 2012-01-03 Amgen Inc. Thiazole compounds as protein kinase b (pkb) inhibitors
EP1918286B1 (en) * 2006-11-05 2011-12-21 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Thiazolhydrazides for treatment of neurodegenerative diseases
GB0701426D0 (en) * 2007-01-25 2007-03-07 Univ Sheffield Compounds and their use
CA2692713A1 (en) 2007-07-17 2009-01-22 Amgen Inc. Heterocyclic modulators of pkb
WO2009011871A2 (en) * 2007-07-17 2009-01-22 Amgen Inc. Thiadiazole modulators of pkb
US8703761B2 (en) 2008-07-15 2014-04-22 Novartis Ag Organic compounds
JP5705748B2 (ja) 2009-02-18 2015-04-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｂ２受容体を変調する複素環化合物
WO2010126002A1 (ja) * 2009-04-28 2010-11-04 塩野義製薬株式会社 ヘテロ環スルホンアミド化合物を含有する医薬
US8299103B2 (en) * 2009-06-15 2012-10-30 Boehringer Ingelheim International Gmbh Compounds which selectively modulate the CB2 receptor
JP2013517271A (ja) 2010-01-15 2013-05-16 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｂ２受容体を調節する化合物
US8846936B2 (en) 2010-07-22 2014-09-30 Boehringer Ingelheim International Gmbh Sulfonyl compounds which modulate the CB2 receptor
CN102351854B (zh) * 2011-07-29 2014-06-04 华中科技大学 氨基噻唑衍生物及制备方法和医药用途
DK2970272T3 (en) * 2013-03-14 2019-04-23 Merck Patent Gmbh glycosidase
EP2803668A1 (en) 2013-05-17 2014-11-19 Boehringer Ingelheim International Gmbh Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles
CN103435573B (zh) * 2013-07-16 2015-04-01 浙江医药高等专科学校 苄基取代的噻唑并环己烷类化合物、其制备方法和用途
CN103408541B (zh) * 2013-07-16 2015-04-01 浙江医药高等专科学校 吲哚取代的噻唑并环己烷类化合物、及其抗肿瘤用途
GB201401886D0 (en) * 2014-02-04 2014-03-19 Lytix Biopharma As Neurodegenerative therapies
WO2018235966A1 (ja) * 2017-06-21 2018-12-27 第一三共株式会社 Ｅｐ３００／ｃｒｅｂｂｐ阻害剤

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992021360A1 (en) * 1991-05-28 1992-12-10 Merck & Co., Inc. Substituted n-carboxyalkylpeptidyl derivatives as antidegenerative active agents
CO5021134A1 (es) * 1998-05-01 2001-03-27 Abbott Lab Inhibidores beta-aminoacidos substituidos de aminopeptida- sa-2 metionina
WO1999057098A2 (en) * 1998-05-01 1999-11-11 Abbott Laboratories Substituted beta-amino acid inhibitors of methionine aminopeptidase-2
WO2000024392A1 (fr) * 1998-10-26 2000-05-04 Sumitomo Pharmaceuticals Company, Limited Inhibiteur de la formation de beta-amyloide
AR039059A1 (es) * 2001-08-06 2005-02-09 Sanofi Aventis Compuesto derivado de acilaminotiazol, su utilizacion, procedimientos para prepararlo, composicion farmaceutica que lo comprende, y compuestos intermediarios
FR2842523A1 (fr) * 2002-07-17 2004-01-23 Sanofi Synthelabo Derives d'acylaminothiazole, leur preparation et leur application en therapeutique

Also Published As

Publication number Publication date
PL376171A1 (en) 2005-12-27
CR7785A (es) 2005-07-08
MA27451A1 (fr) 2005-07-01
NO20052223L (no) 2005-07-04
ECSP055719A (es) 2005-07-06
BR0314611A (pt) 2005-07-26
AU2003265068A1 (en) 2004-05-04
JP2006504796A (ja) 2006-02-09
TNSN05104A1 (fr) 2007-05-14
CN1688557A (zh) 2005-10-26
AR043051A1 (es) 2005-07-13
PE20040640A1 (es) 2004-09-15
WO2004033439A1 (en) 2004-04-22
EP1551815A1 (en) 2005-07-13
NL1024499A1 (nl) 2004-04-13
TW200420550A (en) 2004-10-16
NL1024499C2 (nl) 2004-10-13
GT200300219A (es) 2004-05-18
MXPA05002420A (es) 2005-10-05
IS7738A (is) 2005-03-10
AP2005003274A0 (en) 2005-06-30
PA8585001A1 (es) 2004-12-16
CA2501803A1 (en) 2004-04-22
OA12937A (en) 2006-10-13
KR20050070046A (ko) 2005-07-05
UY28011A1 (es) 2004-04-30
ZA200502841B (en) 2006-03-29
NO20052223D0 (no) 2005-05-06
US20040152747A1 (en) 2004-08-05

Similar Documents

Publication Publication Date Title
CO5550435A2 (es) Compuestos de tiazol para el tratamiento de transtornos neu- rodegenerativos
CU20110190A7 (es) Análogos de isoxazol-3(2h)-ona como agentes terapéuticos
RS50595B (sr) Jedinjenja imidazola za lečenje neurodegenerativnih poremećaja
ECSP099395A (es) Nuevos derivados de los ácidos amino-nicotínico y amino-isonicotínico
CU23926B1 (es) Derivado de oxopirazina y herbicida
ES2452299T3 (es) Compuestos heterocíclicos fungicidas
AR061642A1 (es) Derivados de ureas de tropano, su preparacion y su aplicacion en terapeu-tica, procesos de obtencion y composiciones farmaceuticas
PA8785001A1 (es) Compuestos estables en agua, catalizadores y reacciones catalizadas novedosos
ES2647664T3 (es) Compuestos de indol o análogos de los mismos útiles para el tratamiento de la degeneración macular relacionada con la edad (AMD)
AR056560A1 (es) Pirrolopiridinonas como moduladores cb1
UY31014A1 (es) Derivados de ftalazinona
CO6321130A2 (es) Piridinas carboxamidas como inhibidores de la 11 beta-hsd1
AR069796A1 (es) Derivados de bencimidazol, sustituido por carboxilo o por hidroxilo, proceso para prepararlos y composiciones farmaceuticas que los contienen
AR064459A1 (es) Derivados de sulfonamida
CO5650235A2 (es) Derivados de imidazol
AR049418A1 (es) Derivados de heteroarilaminopirazol y composiciones farmaceuticas para el tratamiento de la diabetes.
AR066421A1 (es) Compuestos derivados de piridona
NO20070225L (no) Anvendelse av litiumsalter av fettalkoholsulfater for rensing av borehull, boreinnretninger og borefinfraksjoner
AR054583A1 (es) Pantoprazol isotopicamente sustituido
MY147843A (en) Fluorine-containing organosulfur compound and pesticidal composition thereof
MX2009012338A (es) Compuestos organicos de azufre y su uso para controlar artropodos dañinos.
WO2009008447A1 (ja) 触媒組成物及びそれを用いたクロスカップリング化合物の製造方法
AR046753A1 (es) Derivados de benzoxazina y usos de los mismos
MX2009012346A (es) Compuestos organicos de azufre y su uso para controlar artropodos dañinos.
AR041080A1 (es) Compuestos de 5- croman- 5- il- etilamina substituidos y su uso para el tratamiento de glaucoma

Legal Events

Date Code Title Description
FC Application refused